Mackenzie M. Lieberman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mackenzie M. Lieberman has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Scott H. Olejniczak
Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA
16 shared publications - A. J. Robert McGray
Roswell Park Comprehensive Cancer Center
14 shared publications - Bryan M. Gillard
Roswell Park Comprehensive Cancer Center 1 Buffalo, NY
14 shared publications - Colin Chavel
Roswell Park Comprehensive Cancer Center 1 Department of Immunology Buffalo, New York
14 shared publications - Jason H. Tong
Roswell Park Comprehensive Cancer Center 1 Department of Immunology Buffalo, New York
14 shared publications - Jonathan L. Bramson
Department of Medicine, McMaster University, Hamilton, Canada
14 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 7 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
CD86 expression on patient MM cells prior to CAR T therapy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 7 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
CD86 expression on patient MM cells prior to CAR T therapy.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 3 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of CAR T cell mitochondrial metabolism.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 3 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of CAR T cell mitochondrial metabolism.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Key Resources Table 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Key Resources Table 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessKey Resources Table 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Key Resources Table 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 8 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Effect of transient abatacept exposure on MM.1S growth.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 8 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Effect of transient abatacept exposure on MM.1S growth.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 2 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of human and mouse CD28 knockout CAR T cells, and mouse myeloma target cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 2 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of human and mouse CD28 knockout CAR T cells, and mouse myeloma target cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 6 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of short duration of CD28 blockade in mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 6 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of short duration of CD28 blockade in mice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 5 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
In vivo CAR T cell characterization.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 5 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
In vivo CAR T cell characterization.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of human hBCMABBζ CAR T cells and myeloma target cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of human hBCMABBζ CAR T cells and myeloma target cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Gating Strategies 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Gating strategies used to identify cell populations of interest.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Gating Strategies 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Gating strategies used to identify cell populations of interest.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 4 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
In vitro CAR T cell proliferation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 4 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
In vitro CAR T cell proliferation.